Cited by 2,003Bone health and osteoporosis researchBone health and treatmentsHip and Femur Fractures

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

Zoledronic Acid and Clinical Fractures and Mortality after Hip Fracture

Open access

Lyles, Kenneth W., Colón-Emeric, Cathleen S., Magaziner, Jay S., Adachi, Jonathan D., Pieper, Carl F., Mautalen, Carlos, Hyldstrup, Lars, Recknor, Chris, Nordsletten, Lars, Moore, Kathy A., Lavecchia, Catherine, Zhang, Jie, Mesenbrink, Peter, Hodgson, Patricia K., Abrams, Ken, Orloff, John J., Horowitz, Zebulun, Eriksen, Erik Fink, Boonen, Steven·2007·New England Journal of Medicine

DOI 10.1056/nejmoa074941PMC PMC2324066

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Mortality is increased after a hip fracture, and strategies that improve outcomes are needed. METHODS: In this randomized, double-blind, placebo-controlled trial, 1065 patients were assigned to receive yearly intravenous zoledronic acid (at a dose of 5 mg), and 1062 patients were assigned to receive placebo. The infusions were first administered within 90 days after surgical repair of a hip fracture. All patients (mean age, 74.5 years) received supplemental vitamin D and calcium. The median follow-up was 1.9 years. The primary end point was a new clinical fracture. RESULTS: The rates of any new clinical fracture were 8.6% in the zoledronic acid group and 13.9% in the placebo group, a 35% risk reduction with zoledronic acid (P=0.001); the respective rates of a new clinical vertebral fracture were 1.7% and 3.8% (P=0.02), and the respective rates of new nonvertebral fractures were 7.6% and 10.7% (P=0.03). In the safety analysis, 101 of 1054 patients in the zoledronic acid group (9.6%) and 141 of 1057 patients in the placebo group (13.3%) died, a reduction of 28% in deaths from any cause in the zoledronic acid group (P=0.01). The most frequent adverse events in patients receiving zoledronic acid were pyrexia, myalgia, and bone and musculoskeletal pain. No cases of osteonecrosis of the jaw were reported, and no adverse effects on the healing of fractures were noted. The rates of renal and cardiovascular adverse events, including atrial fibrillation and stroke, were similar in the two groups. CONCLUSIONS: An annual infusion of zoledronic acid within 90 days after repair of a low-trauma hip fracture was associated with a reduction in the rate of new clinical fractures and with improved survival. (ClinicalTrials.gov number, NCT00046254 [ClinicalTrials.gov].).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa074941

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Vitamin D Deficiency
Holick, M. F. (2007) · New England Journal of Medicine · doi:10.1056/nejmra070553 · Cited by 13,720
Vertebral fracture assessment using a semiquantitative technique
Genant, H. K., Wu, C. Y., van Kuijk, C., & Nevitt, M. C. (1993) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650080915 · Cited by 3,691
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Hip fractures in the elderly: A world-wide projection
Cooper, C. C., Campion, G., & Melton, L. J. (1992) · Osteoporosis International · doi:10.1007/bf01623184 · Cited by 3,225
Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis
Black, D. M., Delmas, P. D., Eastell, R., Reid, I. R., Boonen, S., Cauley, J. A., Cosman, F., Lakatos, P., Leung, P. C., Man, Z., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067312 · Cited by 2,986
Self-citation
Effect of Risedronate on the Risk of Hip Fracture in Elderly Women
McClung, M. R., Geusens, P., Miller, P. D., Zippel, H., Bensen, W. G., Roux, C., Adami, S., Fogelman, I., Diamond, T., Eastell, R., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102013440503 · Cited by 1,918
The Medical Dictionary for Regulatory Activities (MedDRA)
Brown, E. G., Wood, L., & Wood, S. (1999) · Drug Safety · doi:10.2165/00002018-199920020-00002 · Cited by 1,396
Medical Expenditures for the Treatment of Osteoporotic Fractures in the United States in 1995: Report from the National Osteoporosis Foundation
Ray, N. F., Chan, J. K., Thamer, M., & Melton, L. J. (1997) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1997.12.1.24 · Cited by 1,281

Flagged first, then by citations

Show all 35 references

Research works printed but not linked: 2

Davidson CW, 2001, N Z Med J, 114, 329
2003, World Health Organ Tech Rep Ser, 921, 1

Sorted by citations

Items 701–800 of 1,000

After the fall: improving osteoporosis treatment following hip fracture
Kuiper, B. W., Graybill, S. D., Tate, J. M., Kaufman, N., & Bersabe, D. K. (2018) · Osteoporosis International · doi:10.1007/s00198-018-4416-x · Cited by 24
Analysis of Related Factors of Brittle Hip Fracture in Postmenopausal Women with Osteoporosis
Zhuang, H., Wang, P., Li, Y., Lin, J., Yao, X., & Xu, H. Y. (2020) · Orthopaedic Surgery · doi:10.1111/os.12605 · Cited by 24
Prevention of Hip Fractures in Long‐Term Care: Relevance of Community‐Derived Data
Crilly, R. G., Hillier, L. M., Mason, M., Gutmanis, I., & Cox, L. (2010) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2010.02766.x · Cited by 24
Osteoporosis in men: its pathophysiology and the role of teriparatide in its treatment
Ebeling, P. (2008) · Clinical Interventions in Aging · doi:10.2147/cia.s3372 · Cited by 24
Bisphosphonate drugs have actions in the lung and inhibit the mevalonate pathway in alveolar macrophages
Munoz, M. A., Fletcher, E. K., Skinner, O. P., Jurczyluk, J., Kristianto, E., Hodson, M. P., Sun, S., Ebetino, F. H., Croucher, D. R., Hansbro, P. M., et al. (2021) · eLife · doi:10.7554/elife.72430 · Cited by 23
Secondary prevention and estimation of fracture risk
Mitchell, P., & Chem, C. (2013) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2013.11.004 · Cited by 23
Prophylactic Fixation Can Be Cost-effective in Preventing a Contralateral Bisphosphonate-associated Femur Fracture
Jiang, S. Y., Kaufman, D. J., Chien, B. Y., Longoria, M., Shachter, R. D., & Bishop, J. A. (2018) · Clinical Orthopaedics and Related Research · doi:10.1097/corr.0000000000000545 · Cited by 23
Comparing the Diagnostic Accuracy of CBCT Grayscale Values with DXA Values for the Detection of Osteoporosis
Sghaireen, M. G., Ganji, K. K., Alam, M. K., Srivastava, K. C., Shrivastava, D., Rahman, S. A., Patil, S. R., & Alhabib, S. (2020) · Applied Sciences · doi:10.3390/app10134584 · Cited by 23
Current and future burden of incident hip fractures in New South Wales, Australia
Stephens, A. S., Toson, B., & Close, J. (2014) · Archives of Osteoporosis · doi:10.1007/s11657-014-0200-5 · Cited by 23
Heart failure in patients treated with bisphosphonates
Grove, E. L., Abrahamsen, B., & Vestergaard, P. F. (2013) · Journal of Internal Medicine · doi:10.1111/joim.12087 · Cited by 23
Quality of life and health status with zoledronic acid and generic alendronate—a secondary analysis of the Rapid Onset and Sustained Efficacy (ROSE) study in postmenopausal women with low bone mass
Hadji, P., Ziller, V., Gamerdinger, D., Spieler, W., Articus, K., Baier, M. L., Moericke, R., & Kann, P. H. (2011) · Osteoporosis International · doi:10.1007/s00198-011-1834-4 · Cited by 23
The Effects of Zoledronic Acid on Serum Lipids in Multiple Myeloma Patients
Gozzetti, A., Gennari, L., Merlotti, D., Salvadori, S., Paola, V. D., Avanzati, A., Franci, B., Marchini, E., Tozzi, M., Campagna, M. S., et al. (2008) · Calcified Tissue International · doi:10.1007/s00223-008-9123-8 · Cited by 23
MURF1 deficiency suppresses unloading-induced effects on osteoblasts and osteoclasts to lead to bone loss
Kondo, H., Ezura, Y., Nakamoto, T., Hayata, T., Notomi, T., Sorimachi, H., Takeda, S., & Noda, M. (2011) · Journal of Cellular Biochemistry · doi:10.1002/jcb.23327 · Cited by 23
Osthole improves therapy for osteoporosis through increasing autophagy of mesenchymal stem cells
Zheng, X.-D., Yu, Y., Shao, B., Gan, N., Chen, L., & Yang, D. (2019) · EXPERIMENTAL ANIMALS · doi:10.1538/expanim.18-0178 · Cited by 23
Results after introduction of a hip fracture care pathway: comparison with usual care
Svenøy, S., Watne, L. O., Hestnes, I., Westberg, M., Madsen, J. E., & Frihagen, F. (2020) · Acta Orthopaedica · doi:10.1080/17453674.2019.1710804 · Cited by 23
Osteoporosis Therapeutics 2020
Kocijan, R., Klaushofer, K., & Misof, B. M. (2020) · Handbook of experimental pharmacology · doi:10.1007/164_2020_373 · Cited by 24
The effect of systemically administrated zoledronic acid on the osseointegration of dental implants
Ayan, M., Dolanmaz, D., Mihmanlı, A., Ayan, A., & Kürkçü, M. (2012) · Oral Diseases · doi:10.1111/j.1601-0825.2012.01948.x · Cited by 23
Effect of Adherence on Lifetime Fractures in Osteoporotic Women Treated With Daily and Weekly Bisphosphonates
Danese, M. D., Badamgarav, E., & Bauer, D. C. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.090506 · Cited by 23
Clinical experience with intravenous zoledronic acid in the treatment of male osteoporosis: evidence and opinions
Ruža, I., Mirfakhraee, S., ORWOLL, E. S., & Gruntmanis, U. (2013) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x13485829 · Cited by 23
Clinical use of denosumab for the treatment for postmenopausal osteoporosis
Lewiecki, E. M. (2010) · Current Medical Research and Opinion · doi:10.1185/03007995.2010.533651 · Cited by 23
Bisphosphonate therapy for osteoporosis: combining optimal fracture risk reduction with patient preference
Beard, M. K. (2011) · Current Medical Research and Opinion · doi:10.1185/03007995.2011.643296 · Cited by 22
Características epidemiológicas y clínicas de las fracturas de cadera en adultos mayores en un hospital público chileno: Experience in 647 Chilean patients aged 60 years or more
Dinamarca‐Montecinos, J. L., Lazcano, G. A., Rubio-Herrera, R., Carrasco-Buvinic, A., & Vásquez, A. (2015) · Revista médica de Chile · doi:10.4067/s0034-98872015001200008 · Cited by 22
Cardiovascular and skeletal safety of zoledronic acid in osteoporosis observational, matched cohort study using Danish and Swedish health registries
Rubin, K. H., Möller, S., Choudhury, A., Zorina, O., Kalsekar, S., Eriksen, E. F., Andersen, M. T., & Abrahamsen, B. (2020) · Bone · doi:10.1016/j.bone.2020.115296 · Cited by 22
Self-citation
Inpatient Zoledronic Acid and Integrated Orthopedic and Fracture Liaison Services Improve Osteoporosis Treatment Rates
Fan, W., Machado, M., Leder, B. Z., Beyer, L., Franco‐Garcia, E., Kronenberg, H. M., Cevallos, S., Espinoza, J., Finkelstein, J. S., & Bolster, M. B. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac508 · Cited by 22
EXTENSIVE EXPERTISE IN ENDOCRINOLOGY: Osteoporosis management
Reid, I. R. (2022) · European Journal of Endocrinology · doi:10.1530/eje-22-0574 · Cited by 23
Impact of Environmental and Epigenetic Changes on Mesenchymal Stem Cells during Aging
Smith, N., Shirazi, S., Cakouros, D., & Gronthos, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076499 · Cited by 23
Post hip fracture orthogeriatric care—a Canadian position paper addressing challenges in care and strategies to meet quality indicators
Khan, A. A., Alrob, H. A., Al-Alwani, H., Ali, D. S., Almonaei, K., Alsarraf, F., Bogoch, E. R., Dandurand, K., Gazendam, A., Juby, A. G., et al. (2023) · Osteoporosis International · doi:10.1007/s00198-022-06640-3 · Cited by 22
Guías 2012 para el diagnóstico, la prevención y el tratamiento de la osteoporosis
Schurman, L., Bagur, A., Claus-Hermberg, H., Messina, O. D., Negri, A. L., Sánchez, A., González, C. D., Diehl, M., Rey, P., Gamba, J., et al. (2013) · Actualizaciones en osteología · Cited by 22
Can an anti-fracture agent heal fractures?
Einhorn, T. A. (2010) · PubMed Central · Cited by 22
Using tablet computers compared to interactive voice response to improve subject recruitment in osteoporosis pragmatic clinical trials: feasibility, satisfaction, and sample size
Mudano, A. S., Gary, L. C., de Oliveira, A., Melton, M. E., Wright, N. C., Curtis, J. R., Delzell, E., Harrington, T. M., Kilgore, M. L., Lewis, C. E., et al. (2013) · Patient Preference and Adherence · doi:10.2147/ppa.s44551 · Cited by 22
Zoledronic acid for the treatment and prevention of primary and secondary osteoporosis
Rizzoli, R. (2009) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x09352920 · Cited by 22
Treatment of osteoporosis in men with bisphosphonates: rationale and latest evidence
Sim, I., & Ebeling, P. R. (2013) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x13500861 · Cited by 22
Osteoporosis in men
Korpi-Steiner, N. L., Milhorn, D. M., & Hammett‐Stabler, C. A. (2014) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2014.03.026 · Cited by 22
Clinical impact of recent genetic discoveries in osteoporosis
Mitchell, B. D., & Streeten, E. A. (2013) · The Application of Clinical Genetics · doi:10.2147/tacg.s52047 · Cited by 23
Osteoporosis in Men: Insights for the Clinician
Adler, R. A. (2011) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x11411600 · Cited by 22
Incidence and Predictors of Multiple Fractures Despite High Adherence to Oral Bisphosphonates: A Binational Population-Based Cohort Study
Hawley, S. J., Javaid, M. K., Rubin, K. H., Judge, A., Arden, N., Vestergaard, P., Eastell, R., Díez‐Pérez, A., Cooper, C. C., Abrahamsen, B., et al. (2015) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2595 · Cited by 22
The effects of zoledronate on the survival and function of human osteoblast-like cells
Huang, K., Cheng, C.-C., Chuang, P., & Yang, T. (2015) · BMC Musculoskeletal Disorders · doi:10.1186/s12891-015-0818-5 · Cited by 22
Non-adherence with bisphosphonates among patients with osteoporosis: impact on fracture risk and healthcare cost
Chodick, G., Moser, S. S., & Goldshtein, I. (2016) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/14737167.2016.1171145 · Cited by 22
Australian and New Zealand Society for Geriatric Medicine: Position Statement - Orthogeriatric Care*
Mak, J. C. S., Wong, E., & Cameron, I. D. (2011) · Australian Journal on Ageing · doi:10.1111/j.1741-6612.2011.00557.x · Cited by 22
Anti-osteoporosis drug use: too little, too much, or just right? The HUNT study, Norway
Hoff, M., Skurtveit, S. O., Meyer, H. E., Langhammer, A., Søgaard, A. J., Syversen, U., Skovlund, E., Abrahamsen, B., Forsmo, S., & Schei, B. (2018) · Osteoporosis International · doi:10.1007/s00198-018-4560-3 · Cited by 22
Friend or Foe? Essential Roles of Osteoclast in Maintaining Skeletal Health
Wang, H., Yang, G., Xiao, Y., Luo, G., Li, G., & Li, Z. (2020) · BioMed Research International · doi:10.1155/2020/4791786 · Cited by 23
Para que a primeira fratura seja a última
Stolnicki, B., & Oliveira, L. G. (2015) · Revista Brasileira de Ortopedia · doi:10.1016/j.rbo.2015.03.009 · Cited by 22
Does a History of Non-Vertebral Fracture Identify Women Without Osteoporosis for Treatment?
Ryder, K. M., Cummings, S. R., Palermo, L., Satterfield, S., Bauer, D. C., Feldstein, A. C., Schousboe, J. T., Schwartz, A. V., & Ensrud, K. E. (2008) · Journal of General Internal Medicine · doi:10.1007/s11606-008-0622-0 · Cited by 22
Osteoporosis in the at-risk asthmatic
Aljubran, S. A., Whelan, G. J., Glaum, M. C., & Lockey, R. F. (2014) · Allergy · doi:10.1111/all.12438 · Cited by 22
Solid-State Forms of Zoledronic Acid: Polymorphism in Hydrates
Ruscica, R. C., Bianchi, M., Quintero, M., Martinez, A. R., & Vega, D. R. (2010) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22223 · Cited by 22
Investigation and management of osteoporosis in aged trauma patients: a treatment algorithm adapted to the German guidelines for osteoporosis
Neuerburg, C., Mittlmeier, L. M., Schmidmaier, R., Kammerlander, C., Böcker, W., Mutschler, W., & Stumpf, U. C. (2017) · Journal of Orthopaedic Surgery and Research · doi:10.1186/s13018-017-0585-0 · Cited by 22
Fractures frequently occur in older cancer patients: the MD Anderson Cancer Center experience
Edwards, B. J.-A., Sun, M., Zhang, X., Holmes, H. M., Song, J., Khalil, P., Karuturi, M. S., Shah, J. B., Dinney, C. P., Gagel, R. F., et al. (2017) · Supportive Care in Cancer · doi:10.1007/s00520-017-3962-7 · Cited by 22
WHO benchmarks for equitable hip-fracture care and osteoporosis treatment in older people
Chandran, M., Thiyagarajan, J. A., Alokail, M. S., Bruyère, O., Harvey, N. C., Rizzoli, R., Veronese, N., & Reginster, J.-Y. (2025) · Nature Reviews Rheumatology · doi:10.1038/s41584-025-01319-5 · Cited by 21
Bisphosphonate therapy in CKD
Damasiewicz, M. J., & Nickolas, T. L. (2019) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000585 · Cited by 21
Daily and Weekly “High Doses” of Cholecalciferol for the Prevention and Treatment of Vitamin D Deficiency for Obese or Multi-Morbidity and Multi-Treatment Patients Requiring Multi-Drugs—A Narrative Review
Płudowski, P., Marcinowska-Suchowierska, E., Асылбекович, Т. Г., Belaya, Z. E., Grant, W. B., Pilz, S., & Holick, M. F. (2024) · Nutrients · doi:10.3390/nu16152541 · Cited by 21
Bisphosphonates in the treatment of metabolic bone diseases
Arantes, H. P., da Silva, A. G., & Lazaretti‐Castro, M. (2010) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302010000200017 · Cited by 21
Osteoporosis and Fragility Fractures
Morley, J. E. (2011) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2011.04.023 · Cited by 21
Diagnosis and treatment of osteoporosis
Park, Y. (2012) · Journal of Korean Medical Association · doi:10.5124/jkma.2012.55.11.1083 · Cited by 21
Patient Perceptions of Osteoporosis Treatment Thresholds
Neuner, J. M., & Schapira, M. M. (2014) · The Journal of Rheumatology · doi:10.3899/jrheum.130548 · Cited by 21
Evaluating the Antifracture Efficacy of Bisphosphonates
Pazianas, M., Epstein, S., & Zaidi, M. (2009) · Reviews on Recent Clinical Trials · doi:10.2174/157488709788186030 · Cited by 21
Effects of Intravenous Zoledronate on Bone Turnover and Bone Density Persist for at Least 11 Years in HIV-Infected Men
Bolland, M. J., Horne, A. M., Briggs, S. E., Thomas, M. G., Reid, I. R., Gamble, G. D., & Grey, A. B. (2019) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3712 · Cited by 21
Use of anti-osteoporosis medication dispensing by patients with hip fracture: could we do better?
Kristensen, P. K., Ehrenstein, V., Shetty, N., & Pedersen, A. B. (2019) · Osteoporosis International · doi:10.1007/s00198-019-05066-8 · Cited by 21
Assessment and management of bone health in women with oestrogen receptor‐positive breast cancer receiving endocrine therapy: position statement summary
Grossmann, M., Ramchand, S. K., Milat, F., Vincent, A. J., Lim, E., Kotowicz, M. A., Hicks, J., & Teede, H. J. (2019) · The Medical Journal of Australia · doi:10.5694/mja2.50280 · Cited by 21
The impact of the AO Foundation on fracture care: An evaluation of 60 years AO Foundation
Joeris, A., Höglinger, M., Meier, F., Knöfler, F., Scholz, S., Brügger, U., Denk, E., Gutzwiller, F., Prein, J., Renner, N., et al. (2019) · Injury · doi:10.1016/j.injury.2019.07.016 · Cited by 21
Bisphosphonate Drug Holidays in Primary Care: When and What to Do Next?
Bauer, D. C., & Abrahamsen, B. (2021) · Current Osteoporosis Reports · doi:10.1007/s11914-021-00660-4 · Cited by 21
Epidemiological transition to mortality and refracture following an initial fracture
Ho-Le, T. P., Tran, T. S., Bliuc, D., Pham, H. M., Frost, S. A., Eisman, J. A., & Nguyen, T. V. (2021) · eLife · doi:10.7554/elife.61142 · Cited by 21
Building healthy bones throughout life: an evidence‐informed strategy to prevent osteoporosis in Australia
Ebeling, P. R., Daly, R. M., Kerr, D. A., & Kimlin, M. G. (2013) · The Medical Journal of Australia · doi:10.5694/mjao12.11363 · Cited by 22
Low acceptance of treatment in the elderly for the secondary prevention of osteoporotic fracture in the acute rehabilitation setting
Berry, S. D., Misra, D., Hannan, M. T., & Kiel, D. P. (2010) · Aging Clinical and Experimental Research · doi:10.1007/bf03324801 · Cited by 21
Time to onset of antifracture efficacy and year-by-year persistence of effect of zoledronic acid in women with osteoporosis
Boonen, S., Eastell, R., Su, G., Mesenbrink, P. G., Cosman, F., Cauley, J. A., Reid, I. R., Claessens, F., Vanderschueren, D., Lyles, K. W., et al. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1605 · Cited by 21
Self-citation
Hip Fracture Management for the Hospital-Based Clinician: A Review of the Evidence and Best Practices
Hughson, J., Newman, J., & Pendleton, R. C. (2011) · Hospital Practice · doi:10.3810/hp.2011.02.374 · Cited by 21
Effects of Zoledronate on Mortality and Morbidity after Surgical Treatment of Hip Fractures
Cengiz, Ö., Polat, G., Karademir, G., Tunç, O. D., Erdil, M., Tuncay, İ., & Şen, C. (2016) · Advances in Orthopedics · doi:10.1155/2016/3703482 · Cited by 21
Lasofoxifene for the prevention and treatment of postmenopausal osteoporosis
Lewiecki, M. E. (2009) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s5645 · Cited by 21
Fracture liaison services: past, present and future
Ganda, K. (2021) · Osteoporosis International · doi:10.1007/s00198-021-05982-8 · Cited by 21
A multidisciplinary approach to post-operative fragility hip fracture care in Thailand – a narrative review
Unnanuntana, A., Kuptniratsaikul, V., Srinonprasert, V., Charatcharoenwitthaya, N., Kulachote, N., Papinwitchakul, L., Wattanachanya, L., & Chotanaphuti, T. (2023) · Injury · doi:10.1016/j.injury.2023.111039 · Cited by 20
Comparison of two different strategies of treatment with zoledronate in HIV ‐infected patients with low bone mineral density: single dose versus two doses in 2 years
Negredo, E., Bonjoch, A., Pérez‐Álvarez, N., Ornelas, A. P. A., Puig, J., Herrero, C., Estany, C., del Río, L., Gregorio, S. D., Echeverría, P., et al. (2015) · HIV Medicine · doi:10.1111/hiv.12260 · Cited by 20
Comparison of hip fracture and osteoporosis medication prescription rates across Canadian provinces
Crilly, R. G., Kloseck, M., Chesworth, B. M., Mequanint, S., Sadowski, E., & Gilliland, J. (2013) · Osteoporosis International · doi:10.1007/s00198-013-2453-z · Cited by 20
Intraosseous Injection of rhBMP-2/Calcium Phosphate Matrix Improves Bone Structure and Strength in the Proximal Aspect of the Femur in Chronic Ovariectomized Nonhuman Primates
Seeherman, H. J., Li, X. J., Smith, E. A., Parkington, J. D., Li, R., & Wozney, J. M. (2013) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.k.00668 · Cited by 20
Monoclonal antibodies for the treatment of osteoporosis
Lewiecki, E. M. (2012) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2012.740006 · Cited by 20
Speeding up the clock: The past, present and future of progeria
Swahari, V., & Nakamura, A. (2015) · Development Growth & Differentiation · doi:10.1111/dgd.12251 · Cited by 20
Once-yearly zoledronic acid and change in abdominal aortic calcification over 3 years in postmenopausal women with osteoporosis: results from the HORIZON Pivotal Fracture Trial
Cai, G., Keen, H. I., Host, L., Aitken, D. A., Laslett, L. L., Winzenberg, T. M., Wluka, A. E., Black, D. M., & Jones, G. (2020) · Osteoporosis International · doi:10.1007/s00198-020-05430-z · Cited by 20
Depicting developing trend and core knowledge of hip fracture research: a bibliometric and visualised analysis
Peng, G., Guan, Z., Hou, Y., Gao, J., Rao, W., Yuan, X., Guo, J., Huang, X., Zhong, Z., & Lin, J. (2021) · Journal of Orthopaedic Surgery and Research · doi:10.1186/s13018-021-02292-x · Cited by 20
Adherence to Anti-Osteoporotic Treatment and Clinical Implications after Hip Fracture: A Systematic Review
Dobre, R., Niculescu, D., Petca, R., Popescu, R.-I., Petca, A. T., & Poiană, C. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11050341 · Cited by 20
Can hip fracture prediction in women be estimated beyond bone mineral density measurement alone?
Geusens, P., van Geel, T. A. C. M., & van den Bergh, J. P. (2010) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x09359541 · Cited by 20
Osteonecrosis of the jaw
Sambrook, P. N., & Ebeling, P. R. (2008) · Current Rheumatology Reports · doi:10.1007/s11926-008-0018-5 · Cited by 20
Hip Fracture-Related Mortality among Older Adults in the United States: Analysis of the CDC WONDER Multiple Cause of Death Data, 1999–2013
Orces, C. H. (2016) · Epidemiology Research International · doi:10.1155/2016/8970259 · Cited by 20
Medical treatment of severe osteoporosis including new concept of advanced severe osteoporosis
Choi, H. S., Park, S. Y., Kim, Y. M., Kim, S. H., Kim, K. M., & Chung, Y. (2016) · Osteoporosis and Sarcopenia · doi:10.1016/j.afos.2016.02.003 · Cited by 20
Safety, pharmacokinetics, and changes in bone metabolism associated with zoledronic acid treatment in Japanese patients with primary osteoporosis
Shiraki, M., Tanaka, S., Suzuki, H., Ueda, S., & Nakamura, T. (2016) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-016-0806-3 · Cited by 20
Metabolic Bone Disease
Lorenzo, J. A., CANALIS, E. M., & Raisz, L. G. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-0324-5.00029-8 · Cited by 20
The Ethics of Placebo in Studies with Fracture End Points in Osteoporosis
Stein, C. M., & Ray, W. A. (2010) · New England Journal of Medicine · doi:10.1056/nejmsb1006120 · Cited by 20
Overdiagnosis of osteoporosis: fact or fallacy?
Compston, J. E. (2015) · Osteoporosis International · doi:10.1007/s00198-015-3220-0 · Cited by 20
Effect on bone turnover markers of once-yearly intravenous infusion of zoledronic acid versus daily oral risedronate in patients treated with glucocorticoids
Devogelaer, J.-P., Sambrook, P., Reid, D. M., Goemaere, S., Ish-Shalom, S., Collette, J., Su, G., Bucci-Rechtweg, C., Papanastasiou, P., & Reginster, J.-Y. (2013) · Rheumatology · doi:10.1093/rheumatology/kes410 · Cited by 19
The impact of a fracture liaison service with in-hospital anti-osteoporosis treatment on subsequent hip fracture and mortality rates—a single-center retrospective study
Yoel, U., Weiss, H. A., Goldbart, A., Siris, E. S., Fisher, D. L., Hassan, L., & Fraenkel, M. (2024) · Osteoporosis International · doi:10.1007/s00198-024-07325-9 · Cited by 19
Guías de práctica clínica para la evaluación y tratamiento de la osteoporosis asociada a enfermedades endocrinas y nutricionales
Reyes‐García, R., Gimeno, E. J., Martín, A. G., Muñoz, M. R., Sáez, J. M. G., Fernández, I. L., Varsavsky, M., Iglesias, S. G., Rodríguez, I. C., Ballesteros-Pomar, M. D., et al. (2012) · Endocrinología y Nutrición · doi:10.1016/j.endonu.2012.01.002 · Cited by 19
Insufficiency and deficiency of vitamin D in elderly patients with fragility fractures of the hip in the Japanese population
Niikura, T., Oe, K., Sakai, Y., Iwakura, T., Fukui, T., Nishimoto, H., Hayashi, S., Matsumoto, T., Matsushita, T., Maruo, A., et al. (2019) · Journal of orthopaedic surgery · doi:10.1177/2309499019877517 · Cited by 19
Secular Trends in the Pharmacologic Treatment of Osteoporosis and Malignancy-Related Bone Disease from 2009 to 2020
CROMER, S. J., D’Silva, K. M., Yu, E. W.-Y., Landon, J. E., Desai, R. J., & Kim, S. C. (2021) · Journal of General Internal Medicine · doi:10.1007/s11606-021-06938-8 · Cited by 19
Management of Osteoporosis Medication after Osteoporotic Fracture
Oh, Y. K., Moon, N. H., & Shin, W. C. (2022) · Hip & Pelvis · doi:10.5371/hp.2022.34.4.191 · Cited by 19
The interplay between bone and heart health as reflected in medication effects: A narrative review
Trost, S. U., Tesfaye, N., & Harindhanavudhi, T. (2023) · Women s Health · doi:10.1177/17455057231165549 · Cited by 19
Comparative Efficacy of Vertebroplasty, Kyphoplasty, and Medical Therapy for Vertebral Fractures on Survival and Prevention of Recurrent Fractures
Levy, H. I., Seydafkan, S., Rice, J. D., Easley, K. A., & Tangpricha, V. (2012) · Endocrine Practice · doi:10.4158/ep11349.or · Cited by 19
Antiresorptive treatment options and bone health in cancer patients—safety profiles and clinical considerations
Hadji, P., Aapro, M., Costa, L., & Gnant, M. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.03.002 · Cited by 19
Clinical efficacy and safety of zoledronic acid in prostate and breast cancer
Doggrell, S. A. (2009) · Expert Review of Anticancer Therapy · doi:10.1586/era.09.95 · Cited by 19
A comprehensive fracture prevention strategy in older adults: The European union geriatric medicine society (EUGMS) statement
Blain, H., Masud, T., Dargent‐Molina, P., Martin, F. C., Rosendahl, E., van der Velde, N., Bousquet, J. J., Benetos, A., Cooper, C. C., Kanis, J. А., et al. (2016) · European Geriatric Medicine · doi:10.1016/j.eurger.2016.04.012 · Cited by 19
Can Bisphosphonates Prevent Recurrent Fragility Fractures? A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Lee, S. Y., Jung, S. H., Lee, S.-U., Ha, Y., & Lim, J. (2018) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2018.02.005 · Cited by 19
The Case for Comanagement and Care Pathways for Osteoporotic Patients with a Hip Fracture
Swart, E. F., Kates, S. L., McGee, S. M., & Ayers, D. C. (2018) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.17.01288 · Cited by 19
Association between the cumulative exposure to bisphosphonates and hospitalization for atherosclerotic cardiovascular events: A population-based study
Casula, M., Olmastroni, E., Galimberti, F., Tragni, E., Corrao, G., Scotti, L., & Catapano, A. L. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.03.021 · Cited by 20
Use of age-dependent FRAX-based intervention thresholds for Singapore
Kanis, J. А., Chandran, M., Chionh, S. B., Ganeson, G., Harvey, N. C., Koh, W., Kwok, T. C. Y., Lau, T. C., Liu, E., Lorentzon, M., et al. (2020) · Archives of Osteoporosis · doi:10.1007/s11657-020-00782-9 · Cited by 19

Authors: Lyles, K. W., Colón-Emeric, C. S., Magaziner, J. S., Adachi, J. D., Pieper, C. F., Mautalen, C., Hyldstrup, L., Recknor, C., Nordsletten, L., Moore, K. A., Lavecchia, C., Zhang, J., Mesenbrink, P., Hodgson, P. K., Abrams, K., Orloff, J. J., Horowitz, Z., Eriksen, E. F., & Boonen, S.
Affiliations: Veterans Health Administration (US)
University of Maryland, Baltimore (US)
McMaster University (CA)
Duke Medical Center (US)
Hvidovre Hospital (DK)
Oslo University Hospital (NO)
Savient Pharmaceuticals (United States) (US)
Novartis (Switzerland) (CH)
KU Leuven (BE)
ORCID: Magaziner, Jay S.
Adachi, Jonathan D.
Pieper, Carl F.
Nordsletten, Lars
Zhang, Jie
Mesenbrink, Peter
Eriksen, Erik Fink
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2007-11
Volume: 357
Issue: 18
Pages: 1799-1809
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa074941
PMC: PMC2324066
OpenAlex: W2163830908
Cited by: 2,003
References: 35
Citations by year: 2026: 53 · 2025: 88 · 2024: 67 · 2023: 75 · 2022: 78 · 2021: 119 · 2020: 104 · 2019: 94 · 2018: 92 · 2017: 79 · 2016: 97 · 2015: 92 · 2014: 106 · 2013: 115 · 2012: 122
FWCI: 160.83
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
PubMed Central (acceptedVersion)
IRIS (submittedVersion)
SERVAL (Université de Lausanne) (submittedVersion)
Funders: Amgen
Eli Lilly and Company
Pfizer
GlaxoSmithKline
Sanofi
Savient Pharmaceuticals
Novo Nordisk
Servier
National Institute on Aging (K23AG024787)
Topics: Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
Health Sciences › Medicine › Oncology › Bone health and treatments
Health Sciences › Medicine › Surgery › Hip and Femur Fractures
Keywords: zoledronic acid, hip fracture, bisphosphonates, fracture prevention, vertebral fractures, non-vertebral fractures, mortality, postoperative treatment, osteoporosis, adverse events, osteonecrosis of the jaw
MeSH terms: Zoledronic Acid, Aged, Aged, 80 and over, Calcium, Diphosphonates, Double-Blind Method, Drug Administration Schedule, Drug Therapy, Combination, Female, Hip Fractures, Humans, Imidazoles, Infusions, Intravenous, Male, Middle Aged, Vitamin D, Bone Density, Survival Analysis, Bone Density Conservation Agents, Fractures, Bone

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Zoledronic Acid and Clinical Fractures and Mortality after Hip Fracture

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks